Status:
UNKNOWN
Evaluation of Erythroferrone as a New Biomarker of Erythropoesis Stimulating Agents
Lead Sponsor:
Association Athletes For Transparency
Collaborating Sponsors:
University of Milan School of Medicine
Centre d'Investigation Clinique Lyon (CIC)
Conditions:
Sports Drug Abuse
Eligibility:
MALE
18-49 years
Phase:
PHASE1
Brief Summary
The main objective of this research is to demonstrate the possible use of erythroferrone (ERFE) as a potential marker of recombinant human erythropoietin (rHuEpo) use to be included in the Athlete Bio...
Eligibility Criteria
Inclusion
- Man between 18 and 49 years old
- Beneficiary of a social protection scheme
- Able to sign informed consent
Exclusion
- Hematocrite\>50% or Hemoglobin\> 17d/dl or Ferritin\<30 ug/l
- Hypersensitivity to the active substance or to any of the excipients ofEPREX
- Erythroblastopenia already reported following treatment with erythropoietin
- Uncontrolled hypertension
- Any medication taken as part of a chronic treatment
- Absence of stable or evolutionary pathology without treatment
- History of convulsion or epilepsy
- History of thrombotic vascular events
- Large blood loss due to an accident, pathological condition or other similar situation.
- Donation of blood or blood transfusion within three months prior to inclusion in the protocol.
Key Trial Info
Start Date :
September 8 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2018
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT03276910
Start Date
September 8 2017
End Date
June 1 2018
Last Update
September 8 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.